GlycoEra Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 35

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $130M

  • Investors
  • 14

GlycoEra General Information

Description

Operator of a biotech company intended for medical needs in inflammatory, autoimmune, and immune-oncology. The company offers a proprietary platform that develops therapeutics with customized and homogenous human glycans assembled onto glycoproteins in a site-specific manner, enabling healthcare companies to understand the role of glycans in human health and diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Einsiedlerstrasse 34
  • 8820 Wädenswil
  • Switzerland
+41 044
Primary Industry
Biotechnology
Other Industries
Other Healthcare Technology Systems
Vertical(s)
Corporate Office
  • Einsiedlerstrasse 34
  • 8820 Wädenswil
  • Switzerland
+41 044

GlycoEra Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

GlycoEra Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Later Stage VC (Series B) 27-May-2025 $130M Completed Clinical Trials - Phase 1
1. Early Stage VC (Series A) 08-Jan-2024 Completed Pre-Clinical Trials
To view GlycoEra’s complete valuation and funding history, request access »

GlycoEra Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
Series A
To view GlycoEra’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

GlycoEra Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biotech company intended for medical needs in inflammatory, autoimmune, and immune-oncology. The company o
Biotechnology
Wädenswil, Switzerland
35 As of 2026

Schlieren, Switzerland
 

Broomfield, CO
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

GlycoEra Competitors (16)

One of GlycoEra’s 16 competitors is LimmaTech Biologics, a Formerly VC-backed company based in Schlieren, Switzerland.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
LimmaTech Biologics Formerly VC-backed Schlieren, Switzerland
Cerecin Venture Capital-Backed Broomfield, CO
Modag Venture Capital-Backed Wendelsheim, Germany
Alzheon Venture Capital-Backed Framingham, MA
Athos Therapeutics Venture Capital-Backed Los Angeles, CA
You’re viewing 5 of 16 competitors. Get the full list »

GlycoEra Patents

GlycoEra Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2025253185-A1 Glycoengineered polypeptides targeting igg4 autoantibodies and uses thereof Pending 08-Apr-2024
WO-2025215516-A1 Glycoengineered polypeptides targeting igg4 autoantibodies and uses thereof Pending 08-Apr-2024
WO-2024218743-A1 Multi-functional molecules comprising glycans and uses thereof Inactive 21-Apr-2023
AU-2024206743-A1 Glycoengineered polypeptides targeting anti-neutrophil autoantibodies and uses thereof Pending 05-Jan-2023
EP-4646221-A1 Glycoengineered polypeptides targeting anti-neutrophil autoantibodies and uses thereof Pending 05-Jan-2023 C12N15/62
To view GlycoEra’s complete patent history, request access »

GlycoEra Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

GlycoEra Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds
Agent Capital Venture Capital Minority
Bristol-Myers Squibb Foundation Limited Partner Minority
Catalio Capital Management Venture Capital Minority
LifeArc Ventures Venture Capital Minority
MP Healthcare Venture Management Corporate Venture Capital Minority
You’re viewing 5 of 14 investors. Get the full list »

GlycoEra FAQs

  • When was GlycoEra founded?

    GlycoEra was founded in 2020.

  • Where is GlycoEra headquartered?

    GlycoEra is headquartered in Wädenswil, Switzerland.

  • What is the size of GlycoEra?

    GlycoEra has 35 total employees.

  • What industry is GlycoEra in?

    GlycoEra’s primary industry is Biotechnology.

  • Is GlycoEra a private or public company?

    GlycoEra is a Private company.

  • What is GlycoEra’s current revenue?

    The current revenue for GlycoEra is .

  • How much funding has GlycoEra raised over time?

    GlycoEra has raised $194M.

  • Who are GlycoEra’s investors?

    Agent Capital, Bristol-Myers Squibb Foundation, Catalio Capital Management, LifeArc Ventures, and MP Healthcare Venture Management are 5 of 14 investors who have invested in GlycoEra.

  • Who are GlycoEra’s competitors?

    LimmaTech Biologics, Cerecin, Modag, Alzheon, and Athos Therapeutics are some of the 16 competitors of GlycoEra.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process